{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:43:13Z","timestamp":1790844193581,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.oooo.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:26:54Z","timestamp":1768494414000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral adverse events associated with anti-tumor necrosis factor-alpha therapies: using a large real-world dataset"],"prefix":"10.1016","volume":"142","author":[{"given":"Stella O.","family":"Oyewole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetokunbo B.","family":"Olawuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osariemen","family":"Okhuaihesuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-9469","authenticated-orcid":false,"given":"Adepitan A.","family":"Owosho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2026.01.001_bib0001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2340\/00015555-2636","article-title":"Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors","volume":"97","author":"Darrigade","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0002","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oooo.2026.01.001_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jcpt.12393","article-title":"Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects","volume":"41","author":"Varela","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.oooo.2026.01.001_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CP202171","article-title":"Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults","volume":"53","author":"Borras-Blasco","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.oooo.2026.01.001_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MAJ.0b013e3182926a23","article-title":"Efficacy of antitumor necrosis factor(alpha) agents on patients with ankylosing spondylitis","volume":"346","author":"Ren","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.oooo.2026.01.001_bib0006","article-title":"Characteristic analysis of adverse reactions of five anti-TNFa agents: a descriptive analysis from WHO-VigiAccess","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.oooo.2026.01.001_bib0008","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.oooo.2026.01.001_bib0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.oooo.2026.01.001_bib0011","article-title":"Safety of TNF-alpha inhibitors: a real-world study based on the US FDA Adverse Event Reporting System database","volume":"103","author":"Zheng","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.oooo.2026.01.001_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gut.2008.163683","article-title":"Dermatological complications and safety of anti-TNF treatments","volume":"58","author":"Kerbleski","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.oooo.2026.01.001_bib0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1556\/OH.2011.28987","article-title":"Adverse events during biological therapy \u2013 focusing on dermatological side-effects]","volume":"152","author":"Nagy","year":"2011","journal-title":"Orv Hetil"},{"key":"10.1016\/j.oooo.2026.01.001_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.crohns.2011.01.003","article-title":"Oral lichen planus after certolizumab pegol treatment in a patient with crohn's disease","volume":"5","author":"Mocciaro","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.oooo.2026.01.001_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2230.2012.04357.x","article-title":"Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus","volume":"37","author":"Worsnop","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0016","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.oooo.2012.08.001","article-title":"Erythema multiforme major following treatment with infliximab","volume":"115","author":"Edwards","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0017","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaad.2009.04.048","article-title":"Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis","volume":"62","author":"Ahdout","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.joms.2023.06.015","article-title":"A summary of the rare reports of osteonecrosis of the jaw associated with tumor necrosis-alpha inhibitors in the United States Food and Drug Administration's Adverse Event Reporting System database","volume":"81","author":"Wichelmann","year":"2023","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2026.01.001_bib0019","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.oooo.2020.12.001","article-title":"Is medication-related osteonecrosis of the jaw associated with tumor necrosis factor-alpha inhibition?","volume":"131","author":"Rosenberg","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0020","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.oooo.2024.07.002","article-title":"Anti-TNF-alpha induced mucous membrane pemphigoid-like disease","volume":"138","author":"Setti","year":"2024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/myc.70040","article-title":"Fungal infections associated with TNF-Inhibitors: a 20-year of a systematic review fungal infections and TNF-inhibitors","volume":"68","author":"Barbosa","year":"2025","journal-title":"Mycoses"},{"key":"10.1016\/j.oooo.2026.01.001_bib0022","first-page":"378","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy?","volume":"11","author":"Decock","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.oooo.2026.01.001_bib0023","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/2326-6066.CIR-15-0017","article-title":"Neutrophils increase oral squamous cell carcinoma invasion through an invadopodia-dependent pathway","volume":"3","author":"Glogauer","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.oooo.2026.01.001_bib0024","doi-asserted-by":"crossref","first-page":"29047","DOI":"10.18632\/oncotarget.25540","article-title":"Oral inflammation promotes oral squamous cell carcinoma invasion","volume":"9","author":"Goertzen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.oooo.2026.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.oraloncology.2008.02.012","article-title":"Genetic association of cytokine DNA polymorphisms with head and neck cancer","volume":"44","author":"Serefoglou","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.14712\/fb2013059020099","article-title":"Salivary levels of TNF-alpha and IL-6 in patients with oral premalignant and malignant lesions","volume":"59","author":"Juretic","year":"2013","journal-title":"Folia Biol (Praha)"},{"key":"10.1016\/j.oooo.2026.01.001_bib0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cdp.2004.10.003","article-title":"NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma","volume":"29","author":"Rhodus","year":"2005","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.oooo.2026.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cancers15061841","article-title":"Tumour necrosis factor alpha (TNF-alpha) and oral squamous cell carcinoma","volume":"15","author":"Brierly","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.oooo.2026.01.001_bib0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12865-025-00713-8","article-title":"Natural and induced immune responses in oral cavity and saliva","volume":"26","author":"Matsuoka","year":"2025","journal-title":"BMC Immunol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00046-25","article-title":"Synergistic induction of PGE2 by oral pathogens and TNF promotes gingival fibroblast-driven stromal-immune cross-talk in periodontitis","volume":"16","author":"Nieboga","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.oooo.2026.01.001_bib0031","article-title":"Editorial: Oral mucosal immunity: homeostasis and inflammation","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.oooo.2026.01.001_bib0032","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000500575","article-title":"Refractory oral ulcer responsive to infliximab: a case report","volume":"81","author":"Ito","year":"2019","journal-title":"ORL J Otorhinolaryngol Relat Spec"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440326000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440326000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:05:44Z","timestamp":1779192344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440326000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2212440326000064"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2026.01.001","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral adverse events associated with anti-tumor necrosis factor-alpha therapies: using a large real-world dataset","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}